

4basebio AG

Heidelberg

- ISIN DE000A2YN801 -

- WKN A2YN80 -

Invitation to the Extraordinary General Meeting (convenience translation)

We hereby invite our shareholders to an extraordinary general meeting of 4basebio AG ("**Company**") to be held on 28. January 2021 at 11:00 a.m.. In doing so, the Company makes use of the possibility of shortening the notice period pursuant to Section 1 (3) of the Act on Measures in Corporate, Cooperative, Association, Foundation and Condominium Law to Combat the Effects of the COVID-19 Pandemic ("GesRuaCOVBekG") in conjunction with the Ordinance on the Extension of Measures in Corporate, Cooperative, Association, Foundation Law to Combat the Effects of the COVID-19 Pandemic ("GesRGenRCOVMVV") dated October 20, 2020. The Extraordinary General Meeting will be held as a virtual General Meeting in accordance with the provisions of Sec. 1 (2) of the GesRuaCOVBekG without the physical presence of shareholders.

A video and audio broadcast (no electronic participation) of the entire meeting will be available live on the Internet at the address

<https://4basebioag.com/extraordinary-general-meeting-2021/>

Shareholders may exercise their voting rights exclusively by postal vote or by granting power of attorney to the proxies nominated by the Company. Please note in particular the regulations on registration for the General Meeting, which is still required.

I. Agenda

1. Election of Supervisory Board members

Mr. Joseph M. Fernández and Mr. Peter Llewellyn-Davies have declared their intention to resign as members of the Supervisory Board with effect from the end of the next Annual General Meeting of the Company. With the convening of the Extraordinary General Meeting, the election of new Supervisory Board members will therefore be necessary.

In accordance with Art. 8 par. 2 sentence 4 of the Articles of Association of the Company, the election of the new Supervisory Board members shall be for the remaining term of office of the departing members, i.e. for the period until the end of the Annual General Meeting which resolves on the ratification of the acts of the Supervisory Board for the fiscal year 2021 (end of the Annual General Meeting 2022). The term of office in each case begins at the end of the Annual General Meeting on 28. January 2021.

The Supervisory Board is composed in accordance with sections 95, 96 (1), 101 (1) of the German Stock Corporation Act (AktG) and, pursuant to section 8 (1) of the Articles of Association, consists of three members, all of whom are to be elected by the Annual General Meeting. The Annual General Meeting is not bound by election proposals.

The Supervisory Board proposes that the following resolution be adopted:

a) Dr. Rainer Herschlein, resident in Stuttgart, attorney-at-law, is elected to the Supervisory Board of the Company, with the proviso that his term of office ends at the close of

the Annual General Meeting which resolves on the ratification of the acts of the Supervisory Board for the fiscal year ending December 31, 2021.

At the time of publication of this agenda item 1, Dr. Rainer Herschlein is a member of the following statutory supervisory boards or comparable German or foreign supervisory bodies of business enterprises:

- ALMATO AG (formerly DATAGROUP Mobile Solutions AG)
- Ming Le Sports Ltd.
- mobileObjects AG

The curriculum vitae of the candidate proposed for election to the Supervisory Board is printed below.

Personal data:

Year of birth: 1971

Profession: Attorney-at-law and partner at the law firm Heuking Kühn Lüer Wojtek in Stuttgart

Professional background:

After his studies, Dr. Rainer Herschlein worked for the law firms CMS Hasche Sigle and GSK Stockmann + Kollegen. Since 2015, Dr. Herschlein has been a partner at law firm Heuking Kühn Lüer Wojtek in Stuttgart and his practice focuses on the legal areas of mergers & acquisitions, venture capital, private equity and private clients.

Training:

Studied law at the University of Saarbrücken, Tübingen and New York. Doctorate at the University of Tübingen.

b) Ms. Eva Katheder, resident in Bad Vilbel, business graduate and self-employed management consultant, is elected to the Supervisory Board of the Company, with the proviso that her term of office ends at the close of the Annual General Meeting that resolves on the formal approval of the acts of the Supervisory Board for the fiscal year ending December 31, 2021.

At the time of publication of this agenda item 1, Eva Katheder is a member of the following statutory supervisory boards or comparable German or foreign supervisory bodies of business enterprises:

- AEE Ahaus-Enscheder AG
- Mistral Media AG
- Heidelberger Beteiligungsholding AG
- Strawtec Group AG
- Balaton Agro Invest Ltd.
- Latonba AG
- Latonba 2.0 AG i.Gr.

- Investunity AG (until January 22, 2021)

The curriculum vitae of the candidate proposed for election to the Supervisory Board is printed below.

Personal data:

Year of birth: 1965

Profession: Independent management consultant

Professional background:

From 1994 to 2001, she worked in various functions at Tengelmann Warenhandelsgesellschaft (WHG), Mülheim/Ruhr, focusing on planning and controlling as well as restructuring. Her last position was responsible for the Food Retail Germany division including investments (non-food, DIY) and market research. From 2002 to 2009, Ms. Eva Katheder worked as an investment manager for DIH Deutsche Industrie Holding GmbH (Frankfurt/Main), primarily for DIH Finanz und Consult GmbH (Private Equity / Venture Capital - among others in the areas of BioTech, Medical Technology, Trade, Production) and additionally from 2005 - 2009 as Managing Director of DIH / HMD Investco S.à.r.l., Luxembourg. Currently, Eva Katheder is the owner of EK - Business Development and Consulting Services, a consulting company she founded in 2010.

Training:

Studied business administration with a focus on accounting and controlling, corporate management and international management in Erlangen-Nuremberg and Dortmund.

2. Resolution on amendments to the Articles of Association

The Executive Board and the Supervisory Board propose that the following resolution be adopted:

- a) Change of the company name:

Section 1 of the Articles of Association shall be reworded as follows:

„§ 1

Company name, registered office and financial year

- 1. The company bears the name 2invest AG*
- 2. It has its headquarters in Heidelberg.*
- 3. The fiscal year of the Company shall be the calendar year."*

- b) Change of the object of the company:

Section 2 of the Articles of Association shall be reworded as follows:

„§ 2

The object of the company

1. *The object of the Company is to acquire, hold, manage and sell equity interests in corporations and partnerships, in particular - but not exclusively - in the biotechnology, life science and IT sectors in Germany and abroad and for any period of time. The Company is entitled to carry out and take over all transactions and measures which are reasonable and useful for this purpose. The Company is further authorized to manage its own assets and to conduct all types of financial transactions and transactions with financial instruments for which a license pursuant to the German Banking Act (KWG) is not required.*
2. *The object of the Company is also the acquisition, exploitation, sale and protection of technologies and intellectual property of the Company or third parties, in particular in the biotechnology, life science and IT sectors, in Germany and abroad and for any period of time.*
3. *The Company is authorized to advise the management or employees of companies in which it holds an interest, as well as of other companies (with the exception of legal and tax advice and the business advice reserved for auditors), and to provide other services for them. The Company may spin off all or part of its operations to affiliated companies. It may carry out its corporate purpose directly or indirectly through companies in which it holds an equity interest; it may also limit itself to the management of equity interests.*
4. *The Company is also authorized to actively hold and manage investments in operating companies and other companies, to assume their management and/or group management as well as to provide strategic planning and consulting services, to assume financing tasks and to assume the management of a group's financial resources.*
5. *Finally, the Company is entitled to engage in all transactions and take all measures that directly or indirectly promote the object of the Company. For this purpose, it may also establish branches in Germany and abroad.*

c) Change on the election of the Supervisory Board Members:

§ 8 of the Articles of Association shall be reworded as follows:

„§ 8

Supervisory Board; composition, term of office

1. *The Supervisory Board shall consist of three persons.*
2. *Unless the general meeting, when electing individual members of the supervisory board to be elected by it or the supervisory board as a whole, decides on a shorter period, the members of the supervisory board shall be elected at the longest for the period until the end of the general meeting which decides on the discharge for the fourth business year after the beginning of the term of office. The financial year in which the term of office begins shall not*

be counted. Re-election is possible. The election of the successor of a member who resigned before the expiry of his term of office shall only be for the remainder of the term of office of the member who resigned. In the event that all members of the Supervisory Board resign before the expiry of their term of office without a successor having already been elected for individual resigning members of the Supervisory Board, the election of new members of the Supervisory Board to be elected shall also be possible for a different term than the remaining term of office of the resigning members of the Supervisory Board.

3. Each member of the Supervisory Board may resign from office without notice if there is good cause. If there is no good cause for resignation, a period of three weeks shall be observed. Resignation from office shall be effected by written declaration to the Executive Board, notifying the Chairman of the Supervisory Board.

4. in deviation from the provision in § 11 para. 7 of these Articles of Association, the resolution of the General Meeting by which members of the Supervisory Board are removed before the expiry of their term of office shall require a majority of at least three quarters of the votes cast."

d) Amendment of the regulation on the remuneration of supervisory board members

§ 10 of the Articles of Association shall be reworded as follows:

„§ 10

Supervisory Board; Compensation

- 1. The compensation of the members of the Supervisory Board is approved by the Annual General Meeting.*
- 2. The Company reimburses the cash expenses of the members of the Supervisory Board. Value added tax shall be reimbursed by the Company insofar as the members of the Supervisory Board are entitled to invoice the Company separately for value added tax and exercise this right.“*

3. Remuneration of the members of the Supervisory Board

The Supervisory Board and the Executive Board propose that the following compensation be resolved for the members of the Supervisory Board:

"In addition to reimbursement of their expenses, the members of the Supervisory Board shall receive a fixed remuneration payable after the end of the fiscal year, which for each fiscal year from beginning of fiscal year 2021 inclusive – pro rata temporis - amount to Euro 5,000.00 for the individual member and twice this amount for the Chairman."

II. Further information and notes

1. Total number of shares and voting rights

At the time of convening this Annual General Meeting, the share capital of the Company amounts to EUR 51,733,386.00. It is divided into 51,733,386 no-par value shares of the Company. At the time of convening this Annual General Meeting, all no-par value shares are entitled to participate and vote. Each no-par share grants one vote at the Annual General Meeting; the total number of votes is therefore 51,733,386. At the time of convening this Annual General Meeting, the Company or the persons attributable to it pursuant to sections 71a et seq. of the German Stock Corporation Act (AktG) do not hold any treasury shares. There are no different classes of shares.

2. Requirements for following the virtual shareholders' meeting on the Internet and exercising voting rights

a) Requirements for following the virtual shareholders' meeting on the Internet

It is not possible for shareholders within the meaning of Section 118 (1) sentence 2 AktG to participate in the Annual General Meeting even without being present at the place of the meeting and without a proxy. It is not possible for shareholders to exercise all or any of their rights in whole or in part by means of electronic communication; in particular, live transmission does not enable participation in the Annual General Meeting within the meaning of Section 118 (1) sentence 2 AktG.

Voting rights may be exercised by shareholders or their proxies exclusively by postal vote or by granting power of attorney to the Company's proxies, as specified in more detail below.

Pursuant to Art. 11 par. 4 of the Articles of Association, only shareholders entered in the Company's share register by the end of January 21, 2021 (24:00 hours) are entitled to attend the virtual Annual General Meeting and exercise their voting rights.

Clear information must be provided to ensure that the registering shareholder can be identified without doubt, for example by stating his full name or his full company name as entered in the share register.

The registration must be received by the Company no later than January 21, 2021, 24:00 hours, at the following address:

4basebio AG
c/o Computershare Operations Center
80249 Munich
Fax: +49 89 30903-74675
E-mail: anmeldestelle@computershare.de

Pursuant to Section 67 (2) sentence 1 AktG, only those persons entered as such in the share register are deemed to be shareholders in relation to the Company. Accordingly, the registration status in the share register on the day of the Annual General Meeting is decisive for the right to participate and for the number of voting rights to which a person entitled to participate in the Annual General Meeting is entitled. For technical reasons, however, no changes will be made to the share register in the period from the end of January 21, 2021 (**technical record date**) to the end of the Annual General Meeting (**stop on changes**). Therefore, the registration status of the share register on the day of the Annual General Meeting corresponds to the status after the last rewrite on January 21, 2021. Shares are not

blocked by registration for the Annual General Meeting. Shareholders can therefore continue to freely dispose of their shares even after registering for the Annual General Meeting.

However, it is pointed out that pursuant to Sec. 405 (3) No. 1 AktG it is an offence to use the shares of another person, whom he is not authorized to represent, to exercise rights at the Annual General Meeting without the latter's consent. Since in relation to the Company with regard to the Annual General Meeting on January 28. Since in relation to the Company with regard to the Annual General Meeting on January 28, 2021 only those persons are deemed to be shareholders who are entered as such in the share register at that time, anyone who acquires shares beforehand but is not yet entered in the share register at the time of the Annual General Meeting has no right to attend or vote if the seller does not authorize or authorize him to attend the Annual General Meeting and exercise his voting rights. All purchasers of shares in the Company not yet entered in the share register are therefore requested to submit transfer applications in good time.

Reference is made to the notification obligation pursuant to Secs. 33 et seq. of the German Securities Trading Act (Wertpapierhandelsgesetz - WpHG) and the legal consequence provided for in Sec. 44 WpHG of the fundamental suspension of all rights arising from the shares in the event of violations of a notification obligation.

b) Image and sound transmission on the Internet

The Annual General Meeting will be held as a virtual Annual General Meeting without the physical presence of the shareholders or their proxies (with the exception of the Company's proxies), Section 1 para. 2 of the Act on Measures in Corporate, Cooperative, Association, Foundation and Condominium Law to Combat the Effects of the COVID-19 Pandemic ("**COVID-19 Act**") in conjunction with the Regulation on the Extension of Measures in Corporate, Cooperative, Association, Foundation Law to Combat the Effects of the COVID-19 Pandemic ("GesRGenRCOVMVV") dated October 20, 2020.

The entire Annual General Meeting will be broadcast on the internet using the Zoom video conferencing tool by way of video and audio transmission. A link to the video and audio transmission of the Annual General Meeting will be provided by the Company no later than the day before the Annual General Meeting at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

made available to the public. Shareholders who have duly registered for the Annual General Meeting are entitled to access this video and audio transmission. The Company will send the registered shareholders access data for dialing into the Annual General Meeting without delay after the end of the registration period.

From a technical point of view, an Internet connection of the usual standard and the use of common Internet browsers (e.g. Chrome or Firefox) are required, but also sufficient, for tracking the virtual AGM. It may be necessary to install the Zoom app.

c) Procedure for voting by absentee ballot

Shareholders may cast their votes by postal vote. Only those shareholders who have registered in good time in accordance with the requirements set out above under II.2 a) "Requirements for following the virtual Annual General Meeting on the internet" are entitled to exercise their voting rights by postal vote.

Votes cast by absentee ballot and changes with regard to absentee ballots already cast may be submitted no later than the end of the general debate on the day of the Annual General

Meeting ("**absentee ballot deadline**") by mail, e-mail or fax using the reply form enclosed with the registration documents to

4basebio AG

Waldhofer Street 102

69123 Heidelberg

or by fax: +49 (0) 6221-64924-72

or by e-mail at: info@4basebioag.com

be made in writing. The date of receipt by the Company shall be decisive for the timeliness of voting. The Company will also publish the voting reply form on the internet at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

be made available for download from the date of convening until the end of the postal voting period. In the event that counter-motions requiring publication (see section 3 b below) or a request for additions to the agenda (see section 3 a below) are submitted, the Company will add the additional voting items to the voting reply form available on the internet. The Company therefore recommends that the option of postal voting is only used after the deadlines for submitting counter-motions and requests for additions to the agenda have expired.

In the event of multiple declarations received from the same shareholder, the declaration received last shall take precedence.

Should an individual vote be held on an agenda item without this having been communicated in advance of the virtual shareholders' meeting, a vote cast on this agenda item as a whole shall also be deemed to be a corresponding vote cast for each item of the individual vote.

d) Proxies; procedure for exercising voting rights by proxy

Shareholders who do not wish to attend the Annual General Meeting in person and/or exercise their voting rights in person may also be represented in exercising their rights by proxy, e.g. an intermediary, a shareholders' association, a voting advisor or another person. The prerequisite for exercising voting rights by proxy is registration for the Annual General Meeting in due form and time.

After timely registration, proxies may be granted until the end of the Annual General Meeting. If a shareholder authorizes more than one person, the Company may reject one or more of them.

The granting of the proxy, its revocation and the proof of authorization vis-à-vis the Company require text form, unless the proxy is granted to a bank, an equivalent institution or company (Section 135 (10), Section 125 (5) AktG), a shareholders' association or another equivalent person pursuant to Section 135 (8) AktG.

Special conditions may apply to the authorization of banks, equivalent institutions or companies (Section 135 (10), Section 125 (5) AktG) as well as shareholders' associations or equivalent persons pursuant to Section 135 (8) AktG; in such cases, shareholders are requested to consult with the proxy in good time with regard to any form of proxy required by the proxy.

Shareholders wishing to authorize a proxy may use the form provided by the Company for this purpose. It will be sent to the duly registered persons together with the access data. In addition, a proxy form can be requested from the Company by any person entitled to vote and is available to shareholders on the Company's website at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

available for download.

The communication channels listed below, in particular also for electronic transmission, are available for the proof of authorization by mail, by fax or by e-mail:

4basebio AG

Waldhofer Street 102

69123 Heidelberg

or by fax: +49 (0) 6221-64924-72

or by e-mail at: info@4basebioag.com

The aforementioned communication channels may also be used if the proxy is to be granted by declaration to the Company; in this case, separate proof of the granting of the proxy is not required. The revocation of a proxy already granted may also be declared directly to the Company via the aforementioned address.

In addition, the Company again offers its shareholders the opportunity to be represented at the Annual General Meeting by the proxy appointed by the Company. In the event of authorization, the proxy appointed by the Company will exercise the voting right in accordance with instructions. Shareholders who wish to authorize the Company-nominated proxy must have duly registered in accordance with the above provisions. If possible, the form for granting powers of attorney and issuing instructions sent with the access data should be used to authorize a proxy appointed by the Company. In addition, a form for granting powers of attorney and issuing instructions, including further information on the conditions of proxy voting, is available to shareholders at the Internet address

<https://4basebioag.com/extraordinary-general-meeting-2021/>

available for download.

For organizational reasons, the authorization of the proxy appointed by the Company and the issuance of instructions to the proxy in text form must be received at the following address by midnight on January 27, 2021:

4basebio AG

Waldhofer Street 102

69123 Heidelberg

or by fax: +49 (0) 6221-64924-72

or by e-mail at: info@4basebioag.com

If the proxy receives power of attorney and instructions by more than one means of transmission, the last duly issued power of attorney with the corresponding instructions received shall be deemed binding. In the event of improperly issued powers of attorney, the proxy will not represent the votes at the Annual General Meeting. If instructions are not completed correctly or are not issued clearly, the proxy bound by the instructions will abstain from voting or not participate in the vote, depending on the voting procedure. Proxies may not exercise voting rights in the case of votes not known in advance of the Annual General Meeting (e.g. procedural motions). Depending on the voting procedure, the proxies bound by instructions will abstain or not participate in the vote in these cases. The same applies to voting

on a countermotion. The Company's proxies may not be instructed to vote on a countermotion or to propose a motion or ask a question.

3. Shareholders' rights

a) Additions to the agenda, Section 122 (2) AktG

Shareholders whose shares together amount to one-twentieth of the share capital or the pro rata amount of EUR 500,000.00 may request that items be placed on the agenda and published; pursuant to Section 124a of the German Stock Corporation Act (AktG), a request received by the Company after the convening of the Annual General Meeting must be made available on the Company's website without undue delay after its receipt by the Company.

The request must be made in writing to the Executive Board of the Company, and each new item must be accompanied by a statement of reasons or a draft resolution. The request must be received by the Company no later than 13 . January 2021, 24:00 hours, at the following address:

4basebio AG
Waldhofer Street 102
69123 Heidelberg

In accordance with Sec. 122 (2) and (1) AktG, the applicant(s) must prove that they have held the shares for at least 90 days prior to the date of receipt of the request and that they will hold the shares until the Executive Board has decided on the request. If the request is not complied with, the applicants have recourse to the courts pursuant to Art. 122 par. 3 AktG.

b) Counter motions and nominations by shareholders, Section 126 (1), Section 127 AktG

In addition, shareholders may submit to the Company counter motions to proposals by the Executive Board and/or Supervisory Board on specific items on the agenda as well as election proposals. Counter motions to be made accessible must be accompanied by a statement of grounds. Counter motions, election proposals and other inquiries from shareholders regarding the Annual General Meeting must be sent exclusively to:

4basebio AG
Waldhofer Street 102
69123 Heidelberg

or by fax: +49 (0) 6221-64924-72

or by e-mail at: info@4basebioag.com

Counter motions and election proposals received by the Company at the aforementioned address **no later than** 14 days before the date of the Annual General Meeting, i.e. by January 13, 2021, 24:00 hours ("counter motion **deadline**"), will be published subject to the further requirements of sections 126, 127 of the German Stock Corporation Act (AktG), including the name of the shareholder and - in the case of motions - the grounds, without undue delay after their receipt on the internet at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

and made accessible to the public. Any comments by the management will also be made available at the above Internet address. The date of receipt by the Company is decisive for the timeliness of the countermotion.

No countermotions or nominations for election may be made during the virtual shareholders' meeting. Admissible countermotions and election proposals duly made within the countermotion period will be treated in the virtual shareholders' meeting as if they had been made at the shareholders' meeting.

c) Shareholder's right to ask questions and obtain information, Sec. 131 (1) AktG in conjunction with Sec. 1 (2) GesRuaCOVekG. Sec. 1 (2) GesRuaCOVBekG

Shareholders have no right to information. Shareholders have the opportunity to ask questions. This does not entail a right to an answer. The Board of Management decides at its own discretion which questions it answers and how. The Board of Management is not required to answer all questions; rather, it can summarize questions and select questions that make sense in the interests of the other shareholders. In doing so, it may give preference to shareholders' associations and institutional investors with significant voting shares. Questions in foreign languages will not be considered.

During the virtual Annual General Meeting, it is possible to ask questions orally or in writing via a "Questions & Answers" function.

In order to ensure the smooth running of the Extraordinary General Meeting, the Company asks registered shareholders to submit questions by no later than January 26, 2021, 24:00 hours. January 2021, 24:00 hours, by way of electronic communication at the e-mail address

info@4basebioag. com

to be submitted. The Executive Board reserves the right to publish questions submitted in advance on the Company's website at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

to answer.

d) Objection to a resolution of the Annual General Meeting

Objections to the minutes against a resolution of the Annual General Meeting pursuant to section 245 no. 1 of the Stock Corporation Act in conjunction with section 1 para. Section 1 (2) sentence 1 no. 4 of the Covid-19 Act may be lodged by shareholders or proxies who have exercised their voting rights from the beginning of the virtual Annual General Meeting until the end of the virtual Annual General Meeting on January 28 . January 2021 by means of electronic communication at the e-mail address

widerspruch@notare-hjw.de

The declaration of opposition must be accompanied by proof of shareholder status, for example by stating his or her full name or full company name as entered in the share register.

4. Further explanations

Further explanations of shareholders' rights pursuant to Section 122 (2), Section 126 (1), Section 127, Section 131 (1) AktG can be found on the Company's website at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

5. Company website

Further information as well as the information to be published pursuant to Section 124a of the German Stock Corporation Act (AktG) can be found on the Company's website at

<https://4basebioag.com/extraordinary-general-meeting-2021/>

6. Privacy information

4basebio AG processes the following categories of your personal data in the course of conducting the main proceedings: Contact data (e.g. name or the e-mail address), information about your shares (e.g. number of shares) and administrative data (e.g. the registration confirmation number). The processing of personal data in the context of the virtual Annual General Meeting is based on Art. 6 (1) lit. c of the General Data Protection Regulation (DSGVO). According to this, processing of personal data is lawful if the processing is necessary for compliance with a legal obligation. 4basebio AG is legally obligated to conduct the General Meeting of Shareholders. In order to comply with this obligation, the processing of the above categories of personal data is essential. You cannot register for the Annual General Meeting without providing your personal data.

4basebio AG is responsible for data processing. The contact details of the responsible person are:

4basebio AG
Management Board
Waldhofer Straße 102

69123 Heidelberg
E-Mail: info@4basebioag.com

Personal data concerning you will not be disclosed to third parties as a matter of principle. By way of exception, third parties are given access to this data if they have been commissioned by 4basebio AG to provide services in connection with the implementation of the Annual General Meeting. These are typical AGM service providers (such as AGM agencies, lawyers or auditors). The service providers only receive personal data to the extent necessary for the provision of the service.

As part of the statutory right to inspect the list of attendees at the Annual General Meeting, other attendees and shareholders may inspect the data recorded about them in the list of attendees. Your personal data will also be published in the context of requests for additions to the agenda or counter motions requiring publication, if these requests are made by you.

The above data will be kept for up to 3 years (but not less than 2 years) after the end of the Annual General Meeting, depending on the individual case, and will then be deleted, unless further processing of the data is still required in the individual case to process applications, decisions or legal proceedings relating to the Annual General Meeting.

You have the right to receive information about the personal data stored about you free of charge upon request. In addition, you have the right to request the correction of incorrect data, the right to request the restriction of processing of data that has been processed too extensively, and the right to request the deletion of personal data that has been processed

unlawfully or stored for too long (insofar as this does not conflict with any legal obligation to retain data and no other reasons pursuant to Art. 17 (3) DSGVO). In addition, you have the right to transfer all data you have provided to us in a common file format (right to "data portability").

To exercise your rights, simply send an e-mail to:

info@4basebioag.com

In addition, you also have the right to complain to a data protection supervisory authority.

Heidelberg, January 2021

4basebio AG

The Management Board